NPV (net present value) discounts an asset’s future cash flows back to today. It answers “if this molecule reaches market as modelled, what is it worth now?” The problem in pharma is the word if: most assets do not reach market.
eNPV (expected NPV) adjusts that value for the probability of getting there. In its simplest form, it weights the present value of future revenue by the probability of success while the investment is largely certain either way.
Why the distinction changes decisions
- Two assets with identical NPV can have very different eNPV once PTRS is applied.
- A large but low-probability asset can rank below a modest, high-probability one.
- Portfolio prioritisation on NPV alone systematically over-values long-shot programmes.
Keeping the model honest
A financial model is only as good as its assumptions and its link to reality. eNPV is most useful when it connects to real inputs - API price, COGS, demand, discount rate, probability of success - and to annual cashflow actuals for comparison against plan, all on the same molecule record as phase gates and risk. That is what lets finance and portfolio leaders prioritise on value that is adjusted for probability and risk, not on optimistic single-scenario NPV.
Try the relationship yourself: adjust probability of success on the interactive model on our capabilities page and watch eNPV move while NPV stays put.